Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006
Omid Hamid(Cedars-Sinai Medical Center), Marcus O. Butler(University of Toronto), Jacob Schachter, Nageatte Ibrahim(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christoph Höeller(Medical University of Vienna), Ewan Brown(Western General Hospital), Euan Walpole(The University of Queensland), Laurent Mortier, Antoni Ribas(University of California, Los Angeles), F. Stephen Hodi(Harvard University), Caroline Robert(Institut Gustave Roussy), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jianmin Long(Merck & Co., Inc., Rahway, NJ, USA (United States)), Adil Daud(University of California, San Francisco)
Cited by 177
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k